AAG
NVCR icon

Armstrong Advisory Group’s NovoCure NVCR Stock Holding History

Armstrong Advisory Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,420
Closed -$100K – 861
2023
Q2 		$100K Hold
2,420
– – 0.01% 236
2023
Q1 		$146K Hold
2,420
– – 0.02% 194
2022
Q4 		$178K Buy
+2,420
New +$182K 0.02% 178

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Armstrong Advisory Group's NVCR Position: Q3 2023 in Review

Armstrong Advisory Group sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 2,420 shares — an estimated $100K sold.

Armstrong Advisory Group first reported a position in NVCR in Q4 2022 and held it in 3 quarters. The position peaked at $178K in Q4 2022. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

  • Armstrong Advisory Group reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
  • Armstrong Advisory Group sold 2,420 NovoCure shares in Q3 2023, an estimated $100K.
  • Armstrong Advisory Group first reported a position in NovoCure in Q4 2022 and held it in 3 quarters.
  • Armstrong Advisory Group's NovoCure position peaked at $178K in Q4 2022.
  • 226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Armstrong Advisory Group's 13F filing for Q3 2023, filed 11 Oct 2023.